×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PSNL – personalis, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PSNL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/13
06:00 am
psnl
Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026
Low
Report
Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026
4/1
04:28 pm
psnl
Personalis to Participate in the 25th Annual Needham Virtual Conference [Yahoo! Finance]
Low
Report
Personalis to Participate in the 25th Annual Needham Virtual Conference [Yahoo! Finance]
4/1
04:01 pm
psnl
Personalis to Participate in the 25th Annual Needham Virtual Conference
Low
Report
Personalis to Participate in the 25th Annual Needham Virtual Conference
3/24
11:12 am
psnl
Morgan Stanley Lowers Personalis (PSNL) Price Target to $10 [Yahoo! Finance]
Low
Report
Morgan Stanley Lowers Personalis (PSNL) Price Target to $10 [Yahoo! Finance]
3/17
04:42 pm
psnl
Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption [Yahoo! Finance]
Low
Report
Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption [Yahoo! Finance]
3/17
04:00 pm
psnl
Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption
Low
Report
Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption
3/12
06:22 am
psnl
Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal® [Yahoo! Finance]
High
Report
Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal® [Yahoo! Finance]
3/12
06:00 am
psnl
Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®
High
Report
Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/8
03:26 pm
psnl
Form SCHEDULE 13G/A Personalis, Inc. Filed by: T. Rowe Price Investment Management, Inc.
Low
Report
Form SCHEDULE 13G/A Personalis, Inc. Filed by: T. Rowe Price Investment Management, Inc.
4/2
04:12 pm
psnl
Form ARS Personalis, Inc. For: Dec 31
Neutral
Report
Form ARS Personalis, Inc. For: Dec 31
4/2
04:05 pm
psnl
Form DEF 14A Personalis, Inc. For: May 12
Neutral
Report
Form DEF 14A Personalis, Inc. For: May 12
3/17
04:59 pm
psnl
Form 4 Personalis, Inc. For: Mar 15 Filed by: Tachibana Aaron
Low
Report
Form 4 Personalis, Inc. For: Mar 15 Filed by: Tachibana Aaron
3/17
04:58 pm
psnl
Form 4 Personalis, Inc. For: Mar 15 Filed by: Moore Stephen Michael
Low
Report
Form 4 Personalis, Inc. For: Mar 15 Filed by: Moore Stephen Michael
3/17
04:55 pm
psnl
Form 4 Personalis, Inc. For: Mar 15 Filed by: Hall Christopher M
Low
Report
Form 4 Personalis, Inc. For: Mar 15 Filed by: Hall Christopher M
3/17
04:54 pm
psnl
Form 4 Personalis, Inc. For: Mar 15 Filed by: Chen Richard
Low
Report
Form 4 Personalis, Inc. For: Mar 15 Filed by: Chen Richard
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/19
Form 3 Personalis, Inc. For: Jun 19 Filed by: Abingworth LLP
20.2%
3/19 Form 4 Personalis, Inc. For: Mar 17 Filed by: West John Stephen 17.0%
3/27 Form 4 Personalis, Inc. For: Mar 25 Filed by: Chen Richard 16.6%
3/25 Form 8-K Personalis, Inc. For: Mar 25 10.1%
4/3 Form DEF 14A Personalis, Inc. For: May 15 8.7%
3/18 Form 4 Personalis, Inc. For: Mar 16 Filed by: Tachibana Aaron 8.3%
11/12 Personalis, Inc. Expands Oncology Portfolio With the Launch of Cancer Whole Genome Sequencing Services 7.0%
12/5 Form 4 Personalis, Inc. For: Dec 03 Filed by: Chen Richard 6.9%
4/9 Personalis (NASDAQ: PSNL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.75 price target on the stock. 6.6%
4/23 Personalis to Announce First Quarter 2020 Financial Results on May 7, 2020 6.2%
3/19 Form 4 Personalis, Inc. For: Mar 17 Filed by: West John Stephen 17.0%
3/27 Form 4 Personalis, Inc. For: Mar 25 Filed by: Chen Richard 16.6%
3/25 Form 8-K Personalis, Inc. For: Mar 25 10.1%
4/3 Form DEF 14A Personalis, Inc. For: May 15 8.7%
3/18 Form 4 Personalis, Inc. For: Mar 16 Filed by: Tachibana Aaron 8.3%
11/12 Personalis, Inc. Expands Oncology Portfolio With the Launch of Cancer Whole Genome Sequencing Services 7.0%
12/5 Form 4 Personalis, Inc. For: Dec 03 Filed by: Chen Richard 6.9%
4/9 Personalis (NASDAQ: PSNL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.75 price target on the stock. 6.6%
4/23 Personalis to Announce First Quarter 2020 Financial Results on May 7, 2020 6.2%
TOP News Decliners
8/13
Q2/2019 6/30/2019 EPS -0.890 ZacksConsensus -0.310 ActVsEst (0.580) - Miss
-18.0%
3/11 Personalis to Announce Fourth Quarter and Full Year 2019 Financial Results on March 25, 2020 -15.8%
9/26 Form 8-K Personalis, Inc. For: Sep 25 -15.6%
10/1 2 Top Stocks That Aren't on Wall Street's Radar [The Motley Fool] -13.2%
11/13 Form 10-Q Personalis, Inc. For: Sep 30 -11.6%
9/9 Personalis, Inc. Enters Into Research Agreement With Invectys to Provide Comprehensive Tumor Immunogenomics Profiling for Clinical Trial -11.5%
9/26 Personalis (NASDAQ: PSNL) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. -9.4%
11/17 Personalis, Inc. to Present New Data at the AACR Tumor Immunology and Immunotherapy Conference -8.7%
7/15 Personalis (NASDAQ: PSNL) is now covered by analysts at Bank of America Corp. They set a "neutral" rating on the stock. -6.8%
2/11 Form 4 Personalis, Inc. For: Feb 07 Filed by: LUDLUM KEN -5.8%
3/11 Personalis to Announce Fourth Quarter and Full Year 2019 Financial Results on March 25, 2020 -15.8%
9/26 Form 8-K Personalis, Inc. For: Sep 25 -15.6%
10/1 2 Top Stocks That Aren't on Wall Street's Radar [The Motley Fool] -13.2%
11/13 Form 10-Q Personalis, Inc. For: Sep 30 -11.6%
9/9 Personalis, Inc. Enters Into Research Agreement With Invectys to Provide Comprehensive Tumor Immunogenomics Profiling for Clinical Trial -11.5%
9/26 Personalis (NASDAQ: PSNL) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. -9.4%
11/17 Personalis, Inc. to Present New Data at the AACR Tumor Immunology and Immunotherapy Conference -8.7%
7/15 Personalis (NASDAQ: PSNL) is now covered by analysts at Bank of America Corp. They set a "neutral" rating on the stock. -6.8%
2/11 Form 4 Personalis, Inc. For: Feb 07 Filed by: LUDLUM KEN -5.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: